Thyroid and antithyroid agents

Quick revision

Levothyroxine replaces thyroid hormone and is titrated against TSH over weeks; methimazole and propylthiouracil block new hormone synthesis in an overactive gland and share one safety concern — agranulocytosis — that both labels ask patients to watch for by symptom, not by routine blood count alone.

• Levothyroxine (T4) is the standard replacement for hypothyroidism of any cause and has a narrow therapeutic index, so its own label specifically flags brand and formulation consistency as clinically meaningful. (1)
• Several common substances reduce levothyroxine absorption enough to matter: calcium and iron supplements, proton pump inhibitors, sucralfate and antacids, plus soybean flour, cottonseed meal, walnuts and high-fibre meals — the label directs dosing at least 4 hours apart from calcium or iron and on an empty stomach roughly 30-60 minutes before breakfast. (1)
• Dose changes are followed by a TSH recheck no sooner than 6 to 8 weeks later in adults, because levothyroxine's own half-life of roughly 6-7 days in euthyroid patients means the new steady state takes weeks to show up. (1)
• Liothyronine is synthetic T3 — faster-acting and shorter-lived than T4 — used far less often than levothyroxine and mentioned here mainly to contrast with it, not as a routine first-line replacement. (4)
• Methimazole and propylthiouracil (the thionamides) both inhibit thyroid peroxidase, the enzyme that iodinates and couples tyrosine residues to build new T4 and T3 — they block new hormone synthesis, they do not destroy hormone already stored in the gland. (4)
• Agranulocytosis is the safety concern both thionamide labels lead with: patients are told to report fever or sore throat immediately rather than to rely on a scheduled blood count, because onset can be abrupt. (2) (3)
• Propylthiouracil carries a boxed warning for severe, sometimes fatal liver injury that methimazole's label does not carry in the same boxed form, which is the main reason methimazole is generally preferred once a thionamide is indicated. (3)
• The one place propylthiouracil is specifically favoured over methimazole is the first trimester of pregnancy, because methimazole carries its own rare but distinct teratogenic risk in that window; guidance generally supports switching back to methimazole for the second and third trimesters. (2) (3)
• Radioactive iodine ablation is a non-drug alternative that gradually destroys thyroid tissue and almost always ends in lifelong levothyroxine replacement; it is mentioned here for context only, not as a dosing or treatment recommendation. (6)

Overview

This class page covers two pharmacologically opposite toolkits under one taxonomy entry because they are managed by the same feedback axis and are frequently taught, and confused, together. On one side is thyroid hormone replacement — levothyroxine as the default, with liothyronine as a faster, shorter-acting synthetic T3 used far less often. On the other side are the thionamides, methimazole and propylthiouracil, which slow down a gland that is producing too much hormone. Both toolkits are ultimately titrated against thyroid-stimulating hormone (TSH) and, where relevant, free T4, but the direction of titration and the drugs used are opposite, which is exactly the distinction exam questions like to probe. (4)

Levothyroxine's defining pharmacological trait is not its mechanism, which is simply supplying the hormone the gland is not making enough of, but its narrow therapeutic index combined with a slew of ordinary substances that blunt its oral absorption. Calcium and iron supplements, proton pump inhibitors, sucralfate, antacids, soy-based foods, high-fibre meals and even the timing of breakfast can all measurably lower how much of an oral dose actually reaches the circulation, which is why the label is specific about empty-stomach dosing and 4-hour separation from calcium or iron. Because bioequivalence between formulations is not automatically guaranteed at this narrow a margin, staying on one specific brand or generic product, rather than switching casually between them, is treated as a genuine clinical safeguard rather than a convenience preference. (1)

Liothyronine supplies T3 directly rather than relying on the body's own peripheral deiodination of T4, so it acts faster and clears faster, and its narrower dosing window makes it a less forgiving agent for routine long-term replacement than levothyroxine. It appears on this page mainly as the contrast case that clarifies why levothyroxine, not liothyronine, is the default: predictable, once-daily, long-half-life dosing is what makes an oral hormone replacement practical for lifelong use. (4)

The thionamides work by a shared mechanism — acting as preferential substrates for thyroid peroxidase and thereby blocking the iodination and coupling steps that build new thyroid hormone — but they diverge sharply on safety. Methimazole is the generally preferred agent because it is dosed once daily, reaches control faster, and does not carry the boxed hepatotoxicity warning that propylthiouracil's label does. Propylthiouracil is reserved for a small number of specific situations: the first trimester of pregnancy, thyroid storm (where its additional inhibition of peripheral T4-to-T3 conversion is clinically useful), and patients who cannot tolerate methimazole and are not candidates for surgery or radioactive iodine. Radioactive iodine ablation itself is mentioned here only as the non-drug alternative that exists alongside these two drug options, not as a treatment recommendation with a dose or protocol. (3) (4) (6)

Classification and drug examples

The class splits cleanly along direction of effect: hormone replacement raises circulating thyroid hormone toward normal, while thionamides lower an overactive gland's own output. A third, non-pharmacological option — radioactive iodine ablation — sits alongside the thionamides as an alternative route to the same goal and is included here only for orientation.

Mechanism of action

The two toolkits act at opposite ends of the same hormone axis. Levothyroxine and liothyronine simply supply the hormone (T4 or T3) that an underactive gland is not making enough of, restoring the negative-feedback signal to the pituitary. Methimazole and propylthiouracil instead enter an overactive gland and act as preferential substrates for thyroid peroxidase (TPO), the enzyme that iodinates tyrosine residues on thyroglobulin and couples them into new T4 and T3 — blocking that step reduces new hormone synthesis without touching hormone already stored in colloid, which is why thionamide onset is not immediate.

Molecular target

Replacement: the thyroid hormone receptor pathway generally (via exogenous T4/T3). Thionamides: thyroid peroxidase (TPO) inside thyroid follicular cells.

Pharmacodynamic effect

Not applicable in the cidal/static sense — replacement restores a physiological hormone level, and thionamides suppress an enzymatic synthesis step rather than killing a cell population.

Effect kinetics

Replacement: steady state and clinical effect build over the drug's own half-life, roughly 6-7 days for levothyroxine, so dose changes are not re-assessed for 6-8 weeks. Thionamides: onset is delayed because pre-formed hormone stored in the gland must first be depleted before new-synthesis blockade lowers circulating levels.

1. Hormone replacement: exogenous T4 (or T3) enters circulation

   Levothyroxine is absorbed in the small intestine and behaves pharmacologically like endogenous T4; roughly 80% of a daily T4 dose is deiodinated peripherally to active T3 or inactive reverse T3. (1)

2. Circulating hormone suppresses TSH via negative feedback

   As T4/T3 levels rise toward normal, pituitary TSH secretion falls proportionately, which is the basis for using TSH as the monitoring target rather than T4 level alone in primary hypothyroidism. (1)

3. Thionamides are taken up by thyroid follicular cells

   Methimazole and propylthiouracil concentrate inside the thyroid gland rather than acting systemically on stored hormone. (5)

4. Thionamides act as preferential TPO substrates, blocking iodination and coupling

   By competing for the peroxidase enzyme, they prevent iodide from being incorporated into tyrosine residues and prevent those residues from coupling into T4 and T3, halting new hormone production. (4) (5)

5. Propylthiouracil adds a second, peripheral action at higher doses

   Beyond its thyroidal TPO effect, propylthiouracil also inhibits the peripheral enzyme that converts T4 to the more potent T3, an extra action methimazole lacks and the reason PTU is favoured in thyroid storm specifically. (4)

Major clinical uses

Pharmacokinetics

• This page gives no dose regimens by design. Selecting a starting dose, titrating it, or switching between levothyroxine formulations is a decision for the treating clinician working from a current prescribing reference and the individual patient's labs.
• Levothyroxine's long half-life is what makes a single daily tablet practical for lifelong replacement, while both thionamides act mainly by depleting a pre-existing hormone store rather than by their own short plasma half-lives — which is why clinical effect for either drug family takes weeks to fully show, not hours. (1) (5)
• Methimazole's renal elimination and PTU's extensive hepatic metabolism mean the two thionamides are cleared quite differently despite sharing the same target enzyme, which is one more reason they are not simply interchangeable milligram-for-milligram. (5) (3)

Adverse effects

Common

• Overdose-pattern symptoms with levothyroxine: Excess replacement produces effects that mirror hyperthyroidism itself — arrhythmia risk, tremor, nervousness, insomnia, heat intolerance and muscle weakness — because the drug is simply supplying more of the same hormone the body would otherwise overproduce. (1) (7)
• Mild rash, arthralgia or gastrointestinal upset with thionamides: Minor hypersensitivity-type reactions are reported with both methimazole and propylthiouracil and do not necessarily require stopping the drug, unlike the serious reactions below. (2)

Serious adverse effects

• Agranulocytosis: The safety concern both thionamide labels centre on; propylthiouracil's label quotes an incidence around 0.2% to 0.5%, typically arising within the first three months of treatment, and methimazole's label describes the same pattern of sudden-onset leukopenia. Patients are told to report fever or sore throat to their clinician immediately rather than waiting for a scheduled complete blood count, since onset can be abrupt. (2) (3)
• Severe liver injury (propylthiouracil): Propylthiouracil carries a boxed warning for severe liver injury and acute liver failure, in some cases fatal or requiring transplantation; the label notes that routine liver function monitoring is not expected to reliably predict this because onset can be rapid and unpredictable. Patients starting propylthiouracil are counselled on symptoms of liver injury and the drug is stopped if these appear, rather than relying solely on scheduled labs to catch it early. (3)
• Hepatotoxicity (methimazole): Methimazole is also associated with liver injury, but of a cholestatic pattern rather than the acute hepatocellular failure described for propylthiouracil, which is one of the reasons methimazole does not carry the same boxed warning. Liver enzymes are checked if symptoms of hepatic dysfunction appear during methimazole therapy. (2)
• Teratogenic effects specific to each thionamide: Methimazole exposure in the first trimester has been linked to rare congenital defects including aplasia cutis and craniofacial, gastrointestinal and umbilical anomalies; propylthiouracil's own teratogenic profile is considered less severe in that window, which is the basis for the trimester-specific drug choice described above. Pregnancy status and trimester are established before starting or continuing either thionamide. (2)
• Vasculitis (propylthiouracil): Rare ANCA-associated vasculitis has been reported with propylthiouracil, occasionally severe enough to cause glomerulonephritis or pulmonary haemorrhage. New joint pain, blood in urine or breathlessness during propylthiouracil treatment warrants prompt clinical evaluation. (3)
• Cardiac effects of over-replacement (levothyroxine): Excess levothyroxine dosing increases risk of atrial fibrillation and other cardiac adverse reactions, particularly in elderly patients or those with existing cardiovascular disease. This is why the label directs starting below full replacement dose in these groups and rechecking TSH at defined intervals rather than adjusting dose more frequently. (1)

Drug-specific effects

• Levothyroxine: Contraindicated in uncorrected adrenal insufficiency, because raising metabolic rate before glucocorticoid replacement is addressed can precipitate an adrenal crisis. (1)
• Methimazole: The label states it is not recommended in the first trimester of pregnancy unless the benefit is judged to outweigh the risk, given its distinct teratogenicity profile. (2)
• Propylthiouracil: Its own label restricts pediatric use to rare cases where methimazole is not tolerated and surgery or radioactive iodine are not appropriate, reflecting the liver-injury risk seen even in children. (3)

Contraindications, precautions and interactions

Contraindications

• Levothyroxine: uncorrected adrenal insufficiency, and known hypersensitivity to the product. (1)
• Methimazole and propylthiouracil: known hypersensitivity to the respective drug or its excipients. (2) (3)

Precautions

• Levothyroxine is not used for weight loss or obesity treatment in euthyroid patients; doses above genuine hormonal need can cause serious, even life-threatening toxicity. (1)
• Elderly patients and those with cardiovascular disease are started on lower levothyroxine doses because of an increased risk of cardiac adverse reactions during titration. (1)
• Pregnancy trimester is specifically weighed when choosing between the two thionamides, given their differing teratogenicity and hepatotoxicity profiles. (2) (3)
• Any fever or sore throat during thionamide therapy is treated as a possible agranulocytosis warning sign until a blood count says otherwise, not dismissed as a routine infection. (2) (3)
• Baseline and symptom-triggered liver function assessment is part of routine care with either thionamide, though the labels are explicit that this cannot reliably prevent propylthiouracil's rapid-onset liver injury. (3)

Drug interactions

• Calcium and iron supplements: Reduce levothyroxine absorption; the label directs separating dosing by at least 4 hours. (1)
• Proton pump inhibitors, sucralfate and antacids: Can lower levothyroxine absorption enough to affect TSH control, supporting consistent dosing timing relative to these agents. (1)
• Soy-based foods, high-fibre meals, walnuts and cottonseed meal: May bind levothyroxine in the gut and decrease its absorption, which is part of why the label recommends taking it on an empty stomach. (1)
• Other hepatotoxic drugs: Concomitant use alongside propylthiouracil adds to hepatic risk and is weighed by the treating clinician against the reason PTU was chosen in the first place. (3)

Comparison tables

High-yield exam pearls

• Thyroid hormone replacement and thionamides act in opposite directions on the same axis, but both are ultimately re-checked against TSH. (4) It is the organising idea for the whole class and the reason both toolkits are taught together despite having opposite pharmacological goals.
• "PTU in the first trimester, methimazole otherwise" is the classic trimester rule for thionamide choice in pregnancy. (2) (3) It resolves a genuine trade-off — methimazole's teratogenicity risk versus PTU's hepatotoxicity risk — rather than being an arbitrary preference.
• Agranulocytosis is taught as a symptom-driven warning (fever, sore throat), not a scheduled-labs-only safeguard. (2) (3) Both thionamide labels tell patients to report symptoms immediately because onset can be abrupt enough that routine monitoring intervals could miss it.
• PTU's extra trick is blocking peripheral T4-to-T3 conversion, which methimazole does not do. (4) It is the pharmacological reason PTU, despite its worse hepatotoxicity profile overall, is specifically favoured in thyroid storm.
• Levothyroxine's absorption interaction list (calcium, iron, PPIs, soy, fibre) is long enough that timing, not just dose, is a monitoring variable. (1) An unexplained TSH change is often an absorption or adherence question before it is a true dose question.
• Radioactive iodine ablation usually converts hyperthyroidism into permanent hypothyroidism. (6) It is the conceptual bridge between the two halves of this class page: the alternative to antithyroid drugs typically ends in needing thyroid hormone replacement anyway.

Common exam traps

• Trap: Assuming methimazole is simply "the safer thionamide" in every situation, including early pregnancy. Actually: Methimazole is generally preferred overall, but propylthiouracil is specifically favoured in the first trimester because methimazole's own teratogenic risk profile is judged worse in that particular window. (2) (3)
• Trap: Treating agranulocytosis monitoring as equivalent to a routine periodic blood count schedule. Actually: Both labels emphasise immediate symptom reporting (fever, sore throat) precisely because onset can be too sudden for a fixed monitoring interval to reliably catch it first. (2) (3)
• Trap: Expecting a levothyroxine dose change to show up on the next TSH drawn a week or two later. Actually: Because of the drug's roughly 6-7 day half-life, the label specifies waiting 6-8 weeks after a dose change before rechecking TSH in adults. (1)
• Trap: Believing PTU's boxed liver warning means methimazole carries no hepatic risk at all. Actually: Methimazole is also associated with liver injury, of a cholestatic pattern, but that risk has not been judged to warrant the same boxed warning as PTU's acute hepatocellular failure risk. (2)

Self-test questions

Answers are hidden until you open them. These questions are written from this page's cited content and are for study only — they are not clinical guidance.

1. Why does levothyroxine's label direct separating its dose from calcium or iron supplements by at least 4 hours?

   • Calcium and iron increase levothyroxine toxicity
   • Calcium and iron reduce levothyroxine's oral absorption
   • Levothyroxine reduces calcium and iron absorption instead
   • There is no pharmacological interaction, only a taste conflict
   Show answer

   Answer: Calcium and iron reduce levothyroxine's oral absorption

   The label lists calcium and iron supplements among substances that reduce levothyroxine absorption, so dosing is separated by at least 4 hours to protect efficacy. (1)

2. Which thionamide is specifically preferred in the first trimester of pregnancy, and why?

   • Methimazole, because it has no teratogenic risk at all
   • Propylthiouracil, because its own teratogenic profile is judged less severe than methimazole's in that window
   • Methimazole, because it crosses the placenta less readily
   • Neither is used in pregnancy under any circumstances
   Show answer

   Answer: Propylthiouracil, because its own teratogenic profile is judged less severe than methimazole's in that window

   Methimazole carries a distinct first-trimester teratogenicity risk (including aplasia cutis and craniofacial anomalies), so propylthiouracil is specifically favoured in that trimester despite its own hepatotoxicity risk. (2) (3)

3. What safety concern do methimazole and propylthiouracil share, and how are patients told to respond to it?

   • Hearing loss; patients are told to get annual audiometry
   • Agranulocytosis; patients are told to report fever or sore throat immediately
   • Weight gain; patients are told to reduce caloric intake
   • Photosensitivity; patients are told to avoid direct sunlight
   Show answer

   Answer: Agranulocytosis; patients are told to report fever or sore throat immediately

   Both thionamide labels warn of agranulocytosis and instruct patients to report fever or sore throat right away rather than waiting for a scheduled blood test, because onset can be abrupt. (2) (3)

4. Why does propylthiouracil have a specific role in thyroid storm that methimazole does not share?

   • It has a longer half-life than methimazole
   • It additionally inhibits peripheral conversion of T4 to the more potent T3
   • It is the only thionamide that can be given intravenously
   • It works faster because it does not need to inhibit thyroid peroxidase
   Show answer

   Answer: It additionally inhibits peripheral conversion of T4 to the more potent T3

   Beyond its thyroidal TPO-inhibiting action shared with methimazole, propylthiouracil also blocks peripheral T4-to-T3 conversion, a second mechanism useful in the acute setting of thyroid storm. (4)

5. How soon after a levothyroxine dose change should TSH typically be rechecked in an adult?

   • The next day
   • After 1 week
   • After 6 to 8 weeks
   • TSH is never rechecked once a stable dose is found
   Show answer

   Answer: After 6 to 8 weeks

   Levothyroxine's label specifies rechecking TSH 6 to 8 weeks after a dosage change in adults, reflecting the drug's roughly week-long half-life and the time needed to reach a new steady state. (1)

6. What typically happens to thyroid function after radioactive iodine ablation for hyperthyroidism?

   • Thyroid function usually normalises permanently without further treatment
   • Most patients become hypothyroid and need lifelong levothyroxine replacement
   • It has no lasting effect on thyroid hormone levels
   • It converts hyperthyroidism into thyroid cancer in most patients
   Show answer

   Answer: Most patients become hypothyroid and need lifelong levothyroxine replacement

   Radioactive iodine gradually destroys thyroid tissue, and most patients subsequently become hypothyroid and require lifelong levothyroxine replacement — the same drug this page opens with. (6)

Frequently asked questions

References

1. SYNTHROID (levothyroxine sodium) tablets — prescribing information DailyMed, U.S. National Library of Medicine
2. METHIMAZOLE tablet — prescribing information DailyMed, U.S. National Library of Medicine
3. PROPYLTHIOURACIL tablet — prescribing information, including boxed warning DailyMed, U.S. National Library of Medicine
4. Thyrotoxicosis StatPearls Publishing / NCBI Bookshelf, 2025
5. Methimazole StatPearls Publishing / NCBI Bookshelf, 2025
6. Radioactive Iodine (I-131) Therapy for Hyperthyroidism and Thyroid Cancer StatPearls Publishing / NCBI Bookshelf, 2025
7. Hyperthyroidism MedlinePlus, U.S. National Library of Medicine

Related drug classes

• Insulins
• Biguanides
• Systemic corticosteroids

Back to the Endocrine and metabolic drugs classification · Pharmacology Study Corner